Intelence

Land: Den Europæiske Union

Sprog: engelsk

Kilde: EMA (European Medicines Agency)

Køb det nu

Indlægsseddel Indlægsseddel (PIL)
28-11-2022
Produktets egenskaber Produktets egenskaber (SPC)
28-11-2022

Aktiv bestanddel:

Etravirine

Tilgængelig fra:

Janssen-Cilag International NV

ATC-kode:

J05AG04

INN (International Name):

etravirine

Terapeutisk gruppe:

Non-nucleoside reverse transcriptase inhibitors, Antivirals for systemic use

Terapeutisk område:

HIV Infections

Terapeutiske indikationer:

Intelence, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human-immunodeficiency-virus-type-1 (HIV-1) infection in antiretroviral-treatment-experienced adult patients and in antiretroviral-treatment-experienced paediatric patients from six years of age.This indication is based on week-48 analyses from two phase-III trials in highly pretreated patients where Intelence was investigated in combination with an optimised background regimen (OBR) which included darunavir/ritonavir. The indication in paediatric patients is based on 48-week analyses of a single-arm, phase-II trial in antiretroviral-treatment-experienced paediatric patients.

Produkt oversigt:

Revision: 30

Autorisation status:

Authorised

Autorisation dato:

2008-08-28

Indlægsseddel

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE USER
INTELENCE 25 MG TABLETS
etravirine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What INTELENCE is and what it is used for
2.
What you need to know before you take INTELENCE
3.
How to take INTELENCE
4.
Possible side effects
5.
How to store INTELENCE
6.
Contents of the pack and other information
1.
WHAT INTELENCE IS AND WHAT IT IS USED FOR
INTELENCE contains the active substance etravirine. INTELENCE belongs
to a group of anti-HIV
medicines called non-nucleoside reverse transcriptase inhibitors
(NNRTIs).
INTELENCE is a medicine used for the treatment of Human
Immunodeficiency Virus (HIV)
infection. INTELENCE works by reducing the amount of HIV in your body.
This will improve your
immune system and reduces the risk of developing illnesses linked to
HIV infection.
INTELENCE is used in combination with other anti-HIV medicines to
treat adults and children
2 years of age and older who are infected by HIV and who have used
other anti-HIV medicines before.
Your doctor will discuss with you which combination of medicines is
best for you.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE INTELENCE
DO NOT TAKE INTELENCE
-
if you are allergic to etravirine or any of the other ingredients of
this medicine (listed in
section 6)
-
if you are taking elbasvir/grazoprevir (a medicine to treat hepatitis
C infection).
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking INTELENCE.
INTELENCE is not a cure for HIV infection. It is part of a t
                                
                                Læs hele dokumentet
                                
                            

Produktets egenskaber

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
INTELENCE 25 mg tablets
INTELENCE 100 mg tablets
INTELENCE 200 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
INTELENCE 25 mg tablets
Each tablet contains 25 mg of etravirine.
Excipient with known effect
Each tablet contains 40 mg lactose (as monohydrate).
Each tablet contains less than 1 mmol sodium (23 mg), and is
essentially sodium-free.
INTELENCE 100 mg tablets
Each tablet contains 100 mg of etravirine.
Excipient with known effect
Each tablet contains 160 mg lactose (as monohydrate).
Each tablet contains less than 1 mmol sodium (23 mg), and is
essentially sodium-free.
INTELENCE 200 mg tablets
Each tablet contains 200 mg of etravirine.
Excipient with known effect
Each tablet contains less than 1 mmol sodium (23 mg), and is
essentially sodium-free.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
INTELENCE 25 mg tablets
Tablet
White to off-white, oval, scored tablet, debossed with “TMC” on
one side.
The tablet can be divided into two equal doses.
INTELENCE 100 mg tablets
Tablet
White to off-white, oval tablet debossed with “T125” on one side
and “100” on the other side.
INTELENCE 200 mg tablets
Tablet
White to off-white, biconvex, oblong tablet debossed with “T200”
on one side.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
INTELENCE, in combination with a boosted protease inhibitor and other
antiretroviral medicinal
products, is indicated for the treatment of human immunodeficiency
virus type 1 (HIV-1) infection in
antiretroviral treatment-experienced adult patients and in
antiretroviral treatment-experienced
paediatric patients from 2 years of age (see sections 4.4, 4.5 and
5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Therapy should be initiated by a physician experienced in the
management of HIV infection.
Posology
INTELENCE must always be given in combination with other
antiretroviral medicinal products.
_Adults_
The recommended dose of etravirine for adults is 200 mg (on
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Indlægsseddel Indlægsseddel bulgarsk 28-11-2022
Produktets egenskaber Produktets egenskaber bulgarsk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport bulgarsk 15-05-2020
Indlægsseddel Indlægsseddel spansk 28-11-2022
Produktets egenskaber Produktets egenskaber spansk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport spansk 15-05-2020
Indlægsseddel Indlægsseddel tjekkisk 28-11-2022
Produktets egenskaber Produktets egenskaber tjekkisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport tjekkisk 15-05-2020
Indlægsseddel Indlægsseddel dansk 28-11-2022
Produktets egenskaber Produktets egenskaber dansk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport dansk 15-05-2020
Indlægsseddel Indlægsseddel tysk 28-11-2022
Produktets egenskaber Produktets egenskaber tysk 28-11-2022
Indlægsseddel Indlægsseddel estisk 28-11-2022
Produktets egenskaber Produktets egenskaber estisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport estisk 15-05-2020
Indlægsseddel Indlægsseddel græsk 28-11-2022
Produktets egenskaber Produktets egenskaber græsk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport græsk 15-05-2020
Indlægsseddel Indlægsseddel fransk 28-11-2022
Produktets egenskaber Produktets egenskaber fransk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport fransk 15-05-2020
Indlægsseddel Indlægsseddel italiensk 28-11-2022
Produktets egenskaber Produktets egenskaber italiensk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport italiensk 15-05-2020
Indlægsseddel Indlægsseddel lettisk 28-11-2022
Produktets egenskaber Produktets egenskaber lettisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport lettisk 15-05-2020
Indlægsseddel Indlægsseddel litauisk 28-11-2022
Produktets egenskaber Produktets egenskaber litauisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport litauisk 15-05-2020
Indlægsseddel Indlægsseddel ungarsk 28-11-2022
Produktets egenskaber Produktets egenskaber ungarsk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport ungarsk 15-05-2020
Indlægsseddel Indlægsseddel maltesisk 28-11-2022
Produktets egenskaber Produktets egenskaber maltesisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport maltesisk 15-05-2020
Indlægsseddel Indlægsseddel hollandsk 28-11-2022
Produktets egenskaber Produktets egenskaber hollandsk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport hollandsk 15-05-2020
Indlægsseddel Indlægsseddel polsk 28-11-2022
Produktets egenskaber Produktets egenskaber polsk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport polsk 15-05-2020
Indlægsseddel Indlægsseddel portugisisk 28-11-2022
Produktets egenskaber Produktets egenskaber portugisisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport portugisisk 15-05-2020
Indlægsseddel Indlægsseddel rumænsk 28-11-2022
Produktets egenskaber Produktets egenskaber rumænsk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport rumænsk 15-05-2020
Indlægsseddel Indlægsseddel slovakisk 28-11-2022
Produktets egenskaber Produktets egenskaber slovakisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport slovakisk 15-05-2020
Indlægsseddel Indlægsseddel slovensk 28-11-2022
Produktets egenskaber Produktets egenskaber slovensk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport slovensk 15-05-2020
Indlægsseddel Indlægsseddel finsk 28-11-2022
Produktets egenskaber Produktets egenskaber finsk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport finsk 15-05-2020
Indlægsseddel Indlægsseddel svensk 28-11-2022
Produktets egenskaber Produktets egenskaber svensk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport svensk 15-05-2020
Indlægsseddel Indlægsseddel norsk 28-11-2022
Produktets egenskaber Produktets egenskaber norsk 28-11-2022
Indlægsseddel Indlægsseddel islandsk 28-11-2022
Produktets egenskaber Produktets egenskaber islandsk 28-11-2022
Indlægsseddel Indlægsseddel kroatisk 28-11-2022
Produktets egenskaber Produktets egenskaber kroatisk 28-11-2022
Offentlige vurderingsrapport Offentlige vurderingsrapport kroatisk 15-05-2020

Søg underretninger relateret til dette produkt